ANDA 212007, held by Exela Pharma Sciences. Zinc Chloride.
As of Nov 21, 2026, ANDA 212007 (Zinc Chloride), held by Exela Pharma Sciences, was first approved by FDA on May 21, 2021, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Zinc Chloride Injection, USP, 1 mg/mL is indicated for use as a supplement to intravenous solutions given for TPN. Administration helps to maintain zinc serum levels and to prevent depletion of endogenous stores, and subsequent deficiency symptoms.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 21, 2021 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Zinc ChlorideEQ 1MG ZINC/ML · injectable;injection | Zinc Chloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters